MedTrace Logo

Phase 2 Study of EPI-743 in Children With Pearson Syndrome

NCT02104336 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2020-11-18

No results posted yet for this study

Summary

Treatment of Pediatric Subjects with Pearson syndrome

Conditions

  • Pearson Syndrome

Interventions

DRUG

EPI-743

EPI-743 is the quinone oxidation product of alpha-tocotrienol

Sponsors & Collaborators

  • Edison Pharmaceuticals Inc

    lead INDUSTRY

Principal Investigators

  • Matthew Klein, MD, FACS · Edison Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2015-11-30
Completion
2016-02-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02104336 on ClinicalTrials.gov